The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer - A phase II study

被引：5
|
作者：
Michels, J.
Geldart, T.
Darby, A.
Craddock, L.
Iveson, A.
Richardson, L.
Iveson, T.
机构：
[1] Southampton Gen Hosp, Oncol Unit, Southampton SO9 4XY, Hants, England
[2] Salisbury Dist Hosp, Oncol Unit, Salisbury, Wilts, England
来源：
CLINICAL ONCOLOGY | 2006年 / 18卷 / 06期
关键词：
advanced colorectal cancer; mitomycin-C; raltitrexed;
D O I：
10.1016/j.clon.2006.01.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aims: To investigate the combination of raltitrexed and mitomycin-C as first-line chemotherapy treatment in patients with advanced colorectal cancer. Materials and methods: A phase II study. Results: In total, 22 patients were treated with a combination of raltitrexed 3 mg/m(2) every 3 weeks and mitomycin-C 7 mg/m(2) every 6 weeks for up to 24 weeks. The study was closed early for safety reasons as there were three unexpected treatment-related deaths. The overall response rate was 20%, and a further 40% achieved stable disease. The median time to progression was 3.9 months and the median overall survival time was 11.6 months. Conclusion: Owing to the potential for increased toxicity, the combination of raltitrexed and mitomycin-C cannot be recommended as first-line treatment in patients with advanced colorectal cancer.
引用
收藏
页码：431 / 435
页数：5
相关论文
共 50 条
  • [1] The combination of Raltitrexed (tomudex) and Mitomycin-C in the treatment of advanced colorectal cancer: A phase-II-study
    Michels, JE
    Harvey, M
    Darby, A
    Iveson, AM
    Nokes, L
    Iveson, TJ
    BRITISH JOURNAL OF CANCER, 2000, 83 : 46 - 46
  • [2] Phase II study of raltitrexed (Tomudex) as second-line treatment in advanced colorectal cancer (ACC)
    Santoro, M
    Santoro, A
    Maiorino, L
    Forestieri, V
    Forestieri, P
    ANNALS OF ONCOLOGY, 1998, 9 : 45 - 45
  • [3] Phase II study of raltitrexed (Tomudex®) in chemotherapy-pretreated patients with advanced colorectal cancer
    Sato, A
    Kurihara, M
    Horikoshi, N
    Aiba, K
    Kikkawa, N
    Shirouzu, K
    Mitachi, Y
    Sakata, Y
    Wakui, A
    ANTI-CANCER DRUGS, 1999, 10 (08) : 741 - 748
  • [4] 'Tomudex' (raltitrexed) plus 5FU combination treatment for patients with advanced colorectal cancer: a Phase I study
    Mayer, S
    Hilger, R
    Muller, C
    Dohmen, D
    Kloeppel, R
    Vanhoefer, U
    Scheulen, ME
    Seeber, S
    Harstick, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S74 - S74
  • [5] Raltitrexed (Tomudex™) in combination treatment for colorectal cancer:: New perspectives
    Van Cutsem, E
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S1 - S2
  • [6] Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer
    Kerr, DJ
    ANTI-CANCER DRUGS, 1997, 8 : S11 - S15
  • [7] PHASE-II TRIAL - MITOMYCIN-C AND METHOTREXATE COMBINATION THERAPY FOR ADVANCED COLORECTAL-CARCINOMA
    BUDMAN, DR
    SCHULMAN, P
    VINCIGUERRA, V
    DEGNAN, T
    CANCER TREATMENT REPORTS, 1981, 65 (5-6): : 535 - 535
  • [8] PHASE-II STUDY OF A 5-FLUOROURACIL, TENIPOSIDE AND MITOMYCIN-C COMBINATION CHEMOTHERAPY IN ADVANCED COLORECTAL CARCINOMAS
    BECOUARN, Y
    CALABET, J
    BRUNET, R
    TUMORI, 1988, 74 (01) : 75 - 77
  • [9] Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study
    Do Hyoung Lim
    Young Suk Park
    Byeong-Bae Park
    Sang Hoon Ji
    Jeeyun Lee
    Keon Woo Park
    Jung Hoon Kang
    Se-Hoon Lee
    Joon Oh Park
    Kihyun Kim
    Won Seog Kim
    Chul Won Jung
    Young-Hyuck Im
    Won Ki Kang
    Keunchil Park
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 10 - 14
  • [10] Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: A phase II study
    Rosati, G
    Rossi, A
    Germano, D
    Reggiardo, G
    Manzione, L
    ANTICANCER RESEARCH, 2003, 23 (3C) : 2981 - 2985
12345